Related Experiment Video
Updated: Jun 18, 2025

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
Published on: June 21, 2018
Pharmacogenomics polygenic risk score: Ready or not for prime time?
Sonal Singh1, Gabriele Stocco2,3, Katherine N Theken4
1Merck & Co., Inc, South San Francisco, California, USA.
Pharmacogenomic Polygenic Risk Scores (PRS) can predict drug response but face challenges. Recommendations include standardizing methods, collaboration, and better infrastructure for clinical use.
Area of Science:
- Pharmacogenomics and Precision Medicine
Background:
- Pharmacogenomic Polygenic Risk Scores (PRS) are tools to predict drug response based on multiple genetic variants.
- Current PRS often rely on disease genetics, limiting their direct applicability to pharmacogenetics.
Purpose of the Study:
- To review the current status of pharmacogenomic PRS.
- To identify opportunities and challenges hindering their clinical implementation.
- To propose recommendations for advancing pharmacogenomic PRS.
Main Methods:
- Review of recent evidence on pharmacogenomic PRS.
- Evaluation of existing challenges in pharmacogenomics research and PRS development.
- Formulation of recommendations for future research and clinical integration.
Main Results:
- Challenges include reliance on disease genetics, small sample sizes, and inconsistent phenotyping.
- Opportunities lie in developing drug-specific PRS and integrating genomic data with clinical predictors.
Conclusions:
- Standardizing phenotyping, enhancing collaboration, and developing new statistical methods are crucial.
- Improved infrastructure, user-friendly tools, patient education, and addressing ethical concerns are necessary for clinical adoption.
More Related Videos
07:31Implementation of a Real-Time Psychosis Risk Detection and Alerting System Based on Electronic Health Records using CogStack
Published on: May 15, 2020
09:38Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease
Published on: November 14, 2017
Related Concept Videos
Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...
Analysis of Population Pharmacokinetic Data
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Human Genetics
The complex relationship between genetics and psychology is observable through common biological components such...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
A recent model describes pravastatin's hepatobiliary excretion,...